Relmada Therapeutics Announces Promotions
This article was originally published in Scrip
Relmada Therapeutics, Inc. has promoted Richard M. Mangano to chief scientific officer and Lisa Nolan to the newly created role of chief business officer. Mangano has experience leading R&D programs and previously held positions in discovery and clinical research at Hoffmann-La Roche, Lederle Laboratories, Wyeth Research, where he was acting therapeutic area director for neuroscience; and Adolor Corp., where he was vice-president of clinical research and development. Previously, Nolan was chief business officer at Topigen Pharmaceuticals, prior to this she was vice-president of global business development and strategic marketing for Skyepharma PLC. Nolan also held various senior positions in business and marketing at West Pharmaceutical Services, Elan Corp., and Zeneca Pharmaceuticals.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.